Teclistamab (Tecvayli) combined with daratumumab has emerged as a strong second-line treatment option for patients with relapsed or refractory multiple myeloma, especially for those who relapse after frontline quadruplet therapy and are not candidates for CAR T-cell therapy. In the phase 3 MajesTEC-3 trial involving 587 patients, the combination significantly outperformed standard therapy. Median progression-free

Trastuzumab pamirtecan (T-Pam; BNT323/DB-1303), a HER2-targeting antibody-drug conjugate, showed promising results in patients with advanced or recurrent HER2-expressing endometrial cancer who had progressed after chemotherapy and immunotherapy. In a phase 2 study of 145 patients with a median follow-up of 13.2 months, the treatment achieved a median progression-free survival of 8.0 months and a median

Results from the phase 3 PANKU-Breast02 trial showed that izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate targeting EGFR and HER3, significantly improved outcomes in patients with previously treated advanced or metastatic triple-negative breast cancer (TNBC). Among 418 patients, iza-bren reduced the risk of disease progression or death by 71%, achieving a median progression-free survival of

An expert discussion highlighted how treatment of desmoid tumors has changed in recent years. Because many of these rare soft-tissue tumors can remain stable or even shrink on their own, doctors now often recommend active monitoring rather than immediate surgery, which has a high risk of recurrence. However, patients with growing or symptomatic tumors usually

A new analysis suggests that zanubrutinib may provide better outcomes than ibrutinib as a first-line treatment for patients with chronic lymphocytic leukemia (CLL). Researchers compared data from two separate Phase 3 clinical trials and adjusted for differences in patient characteristics to create a balanced comparison. The results showed that patients treated with zanubrutinib had a

Results from the Phase 2 ROSETTA Lung-02 study p suggest that pumitamig, an experimental bispecific antibody targeting PD-L1 and VEGF-A, may be a promising first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) when combined with chemotherapy. Among 40 patients enrolled in the study, the treatment achieved a 100% confirmed disease control rate.